Full-Time

Head – Marketing Dupixent

Gastroenterology

Confirmed live in the last 24 hours

Deadline 7/31/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$228.8k - $330.4k/yr

Expert

Cambridge, MA, USA

Travel expectations up to 25% based on business needs

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Market Research
Sales
Risk Management
Marketing
Data Analysis
Requirements
  • Bachelor's degree in business, marketing, or a related field; advanced degree preferred
  • Proven experience (10+ years) in strategic roles within the pharmaceutical or healthcare industry, with a focus on sales, marketing, omnichannel strategy, franchise management, and business transformation
  • Commercial and business acumen: strong track record in the pharma/bio-pharma industry driving commercial success and launching new products in a range of roles inclusive of marketing, sales, market access, and market research
  • Specialty Care experience is required; Immunology launch experience with a deep understanding of the current landscape and/or Gastro experience will be a plus
  • Demonstrated history of experience in the US pharma and access environment
  • Excellent analytical skills with the ability to leverage market research, customer insights; data driven decision-maker; able to distill large amounts of data and information to find the lead story, communicate it effectively to others, and inspire action
  • Strong leadership abilities and experience managing teams, with the capability to influence all levels of the organization and collaborate with cross-functional teams
  • Exceptional communication and presentation skills, with the ability to effectively convey complex strategies
  • Change management experience, with a track record of driving successful business transformations
  • Results-oriented mindset with a focus on achieving measurable business outcomes
  • Strong organizational skills and the ability to manage multiple priorities in a dynamic environment
  • Demonstrated ability to work effectively on matrix teams. Experience in navigating and managing complex alliance partnerships
  • Prioritizes people development and fosters innovation, transformation, and outside the box thinking.
Responsibilities
  • Own the development, execution and performance of a holistic marketing strategy across HCPs and consumers
  • Provide leadership to the US Dupixent Gastro HCP & Consumer brand team to enable development, alignment and execution of strategy
  • Clearly communicate and champion Dupixent EoE brand strategy with key stakeholders internally and across the Alliance
  • Own the gastroenterology governance across cross-functional partners ensuring alignment to market dynamics, strategy and execution
  • Responsible for the overall structure and organization of the Gastro marketing team with 4-5 direct reports and will manage multiple external agencies / consultants
  • Establish and champion a bold ambition focused on Gastro and EoE patients
  • Develop innovative go-to-market strategies to maximize uptake including digital initiatives like next best action and GenAI content generation
  • Key stakeholder in developing the commercial topline forecast including OPEX and P&L management
  • Lead development of competitive strategy for current and future competitors
  • Key strategic partner with the Global team to ensure strategic alignment, collaboration and executional excellence in Gastro
  • Key strategic partner with the US medical, TLL, Patient Support Services and sales teams to ensure strategic alignment, collaboration and executional excellence
  • Provide key insights to influence Sanofi pipeline development for Dupixent Inspire the team to embrace play to win behaviors in every aspect of their work
  • Encourage innovation by setting and cultivating a culture that embraces failing fast and thoughtful risk taking
  • Champion simplification and make critical decisions to simply and create efficiencies for the entire marketing structure
  • Culture and People Development – Attract diverse top talent both from internal and external sources. Thoughtfully create career pathways for accelerate talent with a Sanofi first mindset
  • Travel expectations up to 25% based on business needs.
Desired Qualifications
  • Advanced degree preferred
  • Experience in Immunology launch experience with a deep understanding of the current landscape and/or Gastro experience will be a plus.

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing advanced research and development to create effective therapies and vaccines that improve patient health. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines and over-the-counter products. The company aims to enhance health outcomes and quality of life for people globally by ensuring that its products are safe, effective, and accessible.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.